Merck Jumps On Neurostim Technology, Signing Agreements With Start-Ups

The biotech giant signed a commercial agreement with bioelectronics company Innervia, and the two will work collaboratively on vagus nerve stimulating technologies. 

• Source: Alamy

Merck has entered a collaboration with Innervia, a subsidiary of Barcelona-based Inbrain Neuroelectronics, to develop technologies for vagus nerve stimulation.

The companies will develop graphene-based technologies for neurostimulation that could benefit patients with severe chronic neurological diseases affecting their peripheral...

More from Digital Technologies

More from Medtech Insight

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Planning To Take Part in MDUFA? FDA Wants To Hear From You

 

The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.

Global Medtech Guidance Tracker: June 2025

 
• By 

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.